CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
Lyell Immunopharma, Inc.
Orca Biosystems, Inc.
University of Southern California
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
University Hospital, Toulouse
Center for International Blood and Marrow Transplant Research
Cogent Biosciences, Inc.
Mayo Clinic
Center for International Blood and Marrow Transplant Research
Sir Mortimer B. Davis - Jewish General Hospital
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Pfizer
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Cabaletta Bio
UNC Lineberger Comprehensive Cancer Center
Kyowa Kirin Co., Ltd.
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
Cogent Biosciences, Inc.
UNC Lineberger Comprehensive Cancer Center
Novartis
University of Pittsburgh
Juno Therapeutics, a Subsidiary of Celgene
Acerta Pharma BV
Yale University
Oncternal Therapeutics, Inc
Takara Bio Inc.
Shenzhen University General Hospital
University Hospital Muenster
Celgene
Başakşehir Çam & Sakura City Hospital
Astex Pharmaceuticals, Inc.
OriCell Therapeutics Co., Ltd.
Kyowa Kirin Co., Ltd.
AO GENERIUM
Nordic Nanovector
Intellia Therapeutics
Celgene
Sunnybrook Health Sciences Centre
Lebanese University
Canadian Myeloma Research Group
Yale University